These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 8681408

  • 1. Design and synthesis of 6-chloro-3,4-dihydro-4-methyl-2H-1,4-benzoxazine-8-carboxamide derivatives as potent serotonin-3 (5-HT3) receptor antagonists.
    Kuroita T, Sakamori M, Kawakita T.
    Chem Pharm Bull (Tokyo); 1996 Apr; 44(4):756-64. PubMed ID: 8681408
    [Abstract] [Full Text] [Related]

  • 2. Benzoxazines. II. Synthesis, conformational analysis, and structure--activity relationships of 3,4-dihydro-2H-1,4-benzoxazine-8-carboxamide derivatives as potent and long-acting serotonin-3 (5-HT3) receptor antagonists.
    Kuroita T, Marubayashi N, Sano M, Kanzaki K, Inaba K, Kawakita T.
    Chem Pharm Bull (Tokyo); 1996 Nov; 44(11):2051-60. PubMed ID: 8945770
    [Abstract] [Full Text] [Related]

  • 3. New 5-HT3 (serotonin-3) receptor antagonists. V. Synthesis and structure-activity relationships of pyrrolo[2,1-c][1,4]benzoxazine-6-carboxamides.
    Kato M, Nishino S, Ito K, Yamakuni H, Takasugi H.
    Chem Pharm Bull (Tokyo); 1995 Aug; 43(8):1358-63. PubMed ID: 7553981
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and pharmacology of 3,4-dihydro-3-oxo-1,4-benzoxazine-8-carboxamide derivatives, a new class of potent serotonin-3 (5-HT3) receptor antagonists.
    Kawakita T, Kuroita T, Yasumoto M, Sano M, Inaba K, Fukuda T, Tahara T.
    Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):624-30. PubMed ID: 1611677
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Synthesis of a new class of 2,3-dihydro-2-oxo-1H-benzimidazole-1-carboxylic acid derivatives as highly potent 5-HT3 receptor antagonists.
    Turconi M, Nicola M, Quintero MG, Maiocchi L, Micheletti R, Giraldo E, Donetti A.
    J Med Chem; 1990 Aug; 33(8):2101-8. PubMed ID: 1695682
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Development of potent serotonin-3 (5-HT3) receptor antagonists. I. Structure-activity relationships of 2-alkoxy-4-amino-5-chlorobenzamide derivatives.
    Harada H, Morie T, Hirokawa Y, Yoshida N, Kato S.
    Chem Pharm Bull (Tokyo); 1995 Aug; 43(8):1364-78. PubMed ID: 7553982
    [Abstract] [Full Text] [Related]

  • 10. Antagonistic activity of Y-25130 on 5-HT3 receptors.
    Sato N, Sakamori M, Haga K, Takehara S, Setoguchi M.
    Jpn J Pharmacol; 1992 Aug; 59(4):443-8. PubMed ID: 1331590
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and structure-activity relationships of 4-amino-5-chloro-N-(1,4-dialkylhexahydro-1,4-diazepin-6-yl)-2-methoxybenzamide derivatives, novel and potent serotonin 5-HT3 and dopamine D2 receptors dual antagonist.
    Hirokawa Y, Harada H, Yoshikawa T, Yoshida N, Kato S.
    Chem Pharm Bull (Tokyo); 2002 Jul; 50(7):941-59. PubMed ID: 12130853
    [Abstract] [Full Text] [Related]

  • 12. New 5-HT3 (serotonin-3) receptor antagonists. IV. Synthesis and structure-activity relationships of azabicycloalkaneacetamide derivatives.
    Kato M, Ito K, Nishino S, Yamakuni H, Takasugi H.
    Chem Pharm Bull (Tokyo); 1995 Aug; 43(8):1351-7. PubMed ID: 7553980
    [Abstract] [Full Text] [Related]

  • 13. The function of 5-HT3 receptors on colonic transit in rats.
    Haga K, Asano K, Fukuda T, Kobayakawa T.
    Obes Res; 1995 Dec; 3 Suppl 5():801S-810S. PubMed ID: 8653566
    [Abstract] [Full Text] [Related]

  • 14. Comparison of potencies of 5-HT3 receptor antagonists at inhibiting aversive behavior to illumination and the von Bezold-Jarisch reflex in the mouse.
    Eglen RM, Lee CH, Khabbaz M, Fontana DJ, Daniels S, Kilfoil T, Wong EH.
    Neuropharmacology; 1994 Feb; 33(2):227-34. PubMed ID: 8035908
    [Abstract] [Full Text] [Related]

  • 15. Phenylimidazolidin-2-one derivatives as selective 5-HT3 receptor antagonists and refinement of the pharmacophore model for 5-HT3 receptor binding.
    Heidempergher F, Pillan A, Pinciroli V, Vaghi F, Arrigoni C, Bolis G, Caccia C, Dho L, McArthur R, Varasi M.
    J Med Chem; 1997 Oct 10; 40(21):3369-80. PubMed ID: 9341912
    [Abstract] [Full Text] [Related]

  • 16. GYKI-46 903, a non-competitive antagonist for 5-HT3 receptors.
    Csillik-Perczel V, Bakonyi A, Yemane T, Vitalis B, Horvath E, Solyom S, Szekely JI, Harsing LG.
    Pharmacol Toxicol; 1996 Jul 10; 79(1):32-9. PubMed ID: 8841094
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride.
    Cohen ML, Bloomquist W, Gidda JS, Lacefield W.
    J Pharmacol Exp Ther; 1989 Jan 10; 248(1):197-201. PubMed ID: 2521513
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the receptor selectivity of the H3 receptor antagonists, iodophenpropit and thioperamide: an interaction with the 5-HT3 receptor revealed.
    Leurs R, Tulp MT, Menge WM, Adolfs MJ, Zuiderveld OP, Timmerman H.
    Br J Pharmacol; 1995 Oct 10; 116(4):2315-21. PubMed ID: 8564266
    [Abstract] [Full Text] [Related]

  • 19. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
    Bill DJ, Coleman J, Hallett I, Middlefell VC, Rhodes KF, Fletcher A.
    Br J Pharmacol; 1995 Jul 10; 115(5):775-80. PubMed ID: 8548176
    [Abstract] [Full Text] [Related]

  • 20. Development of potent serotonin-3 (5-HT3) receptor antagonists. II. Structrue-activity relationships of N-(1-benzyl-4-methylhexahydro-1H-1,4- diazepin-6-yl)carboxamides.
    Harada H, Morie T, Hirokawa Y, Terauchi H, Fujiwara I, Yoshida N, Kato S.
    Chem Pharm Bull (Tokyo); 1995 Nov 10; 43(11):1912-30. PubMed ID: 8575032
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.